<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-9 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-9</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-9</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of combination therapy strategies used to overcome late or acquired immunotherapy resistance in melanoma, including details on therapy types, mechanisms of resistance, rationale for combinations, study design, clinical or preclinical outcomes, biomarkers, adverse events, and any reported limitations or failures.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>combination_therapy_name</strong></td>
                        <td>str</td>
                        <td>The name or description of the combination therapy strategy (e.g., anti-PD-1 + BRAF inhibitor, anti-CTLA-4 + MEK inhibitor, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>therapy_components</strong></td>
                        <td>str</td>
                        <td>List of all agents or modalities included in the combination (e.g., pembrolizumab, vemurafenib, radiotherapy, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>mechanism_of_resistance_targeted</strong></td>
                        <td>str</td>
                        <td>Description of the specific mechanism(s) of acquired resistance that the combination aims to overcome (e.g., loss of antigen presentation, upregulation of alternative checkpoints, MAPK pathway reactivation, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>rationale_for_combination</strong></td>
                        <td>str</td>
                        <td>The scientific or clinical rationale for using this combination to overcome resistance (e.g., synergistic immune activation, targeting parallel pathways, reversing immunosuppression, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>study_type</strong></td>
                        <td>str</td>
                        <td>Type of study (e.g., clinical trial phase, preclinical model, retrospective analysis, case report, review, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>patient_population</strong></td>
                        <td>str</td>
                        <td>Description of the patient population or model used (e.g., advanced melanoma patients with acquired resistance to anti-PD-1, mouse model, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>outcomes</strong></td>
                        <td>str</td>
                        <td>Summary of key outcomes (e.g., response rate, progression-free survival, overall survival, duration of response, etc., with numerical values and units if available).</td>
                    </tr>
                    <tr>
                        <td><strong>biomarkers</strong></td>
                        <td>str</td>
                        <td>Any biomarkers identified or used to predict response or resistance (e.g., PD-L1 expression, TMB, gene mutations, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>adverse_events</strong></td>
                        <td>str</td>
                        <td>Summary of notable adverse events or toxicity associated with the combination therapy (e.g., grade 3/4 immune-related adverse events, specific toxicities, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>limitations_or_failures</strong></td>
                        <td>str</td>
                        <td>Any reported limitations, failures, or negative results of the combination strategy (e.g., lack of efficacy, unacceptable toxicity, resistance not overcome, etc.).</td>
                    </tr>
                    <tr>
                        <td><strong>reference</strong></td>
                        <td>str</td>
                        <td>Citation or identifier for the paper (e.g., DOI, PMID, or full citation).</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>